Bio-Techne Corporation
Bio-Techne Reports Q4 and Fiscal 2025 Results; Announces Dividend
Summary
Bio-Techne Corporation announced its financial results for the quarter and fiscal year ended June 30, 2025. The company reported an organic revenue increase of 3% for the quarter and 5% for the year, driven by strong performance in its Protein Sciences segment. However, GAAP EPS for the quarter was a loss of $0.11, and for the year, it was $0.46. Adjusted EPS was $0.53 for the quarter and $1.92 for the year, showing resilience despite market challenges. The company also announced a cash dividend of $0.25 per share. Exhibits include the press release with detailed financial results and segment performance.
Profitelligence Alerts
Get alerts for TECH
Be first to know when Bio-Techne Corporation files with the SEC.
Filing Categories
Exhibits (2)
Advertisement
About Bio-Techne Corporation
Bio-Techne Corporation is a leading developer and manufacturer of high-quality biological products and solutions for the research and clinical diagnostic markets. The company specializes in providing an extensive range of biotechnological tools that support the advancement of life sciences. Key offerings include proteins, antibodies, assay kits, and laboratory services critical for scientific research and drug development. Bio-Techne operates across diverse sectors such as biotechnology, pharmaceuticals, academic research, and healthcare, supplying innovative solutions that facilitate groundbreaking research and therapeutic discoveries. Its products are essential in advancing modern biology and medicine, contributing to significant developments in areas like cancer research, immunology, and cell biology. Bio-Techne’s commitment to innovation and quality makes it a pivotal player in the biotechnology industry, elevating scientific discovery and fostering advancements in personalized medicine and diagnostics. With a strong global presence, Bio-Techne continues to impact the global life sciences landscape profoundly, upholding a legacy of excellence and reliability in the biotechnological sector.
Official SEC Documents
Advertisement